OTCMKTS:INNV

InnovAge News Headlines

$23.76
-0.83 (-3.38 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.56
Now: $23.76
$24.79
50-Day Range
$1.23
MA: $19.49
$26.04
52-Week Range
$20.86
Now: $23.76
$27.18
Volume78,012 shs
Average Volume349,058 shs
Market Capitalization$3.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.1

Headlines

InnovAge (OTCMKTS INNV) News Headlines Today

SourceHeadline
InnovAge (OTCMKTS:INNV) Now Covered by Analysts at CitigroupInnovAge (OTCMKTS:INNV) Now Covered by Analysts at Citigroup
marketbeat.com - March 29 at 2:40 PM
InnovAge Holding Corp. (OTCMKTS:INNV) Given Consensus Rating of "Buy" by AnalystsInnovAge Holding Corp. (OTCMKTS:INNV) Given Consensus Rating of "Buy" by Analysts
americanbankingnews.com - March 29 at 4:50 PM
InnovAge (OTCMKTS:INNV) Now Covered by CitigroupInnovAge (OTCMKTS:INNV) Now Covered by Citigroup
americanbankingnews.com - March 29 at 3:38 PM
Rick Jackson, Jeb Bush team in SPAC to raise $300M - Atlanta Business Chronicle - Atlanta Business ChronicleRick Jackson, Jeb Bush team in SPAC to raise $300M - Atlanta Business Chronicle - Atlanta Business Chronicle
bizjournals.com - March 29 at 3:11 PM
UPDATE: Piper Sandler Starts Innovage Holding Corp (INNV) at Overweight - StreetInsider.comUPDATE: Piper Sandler Starts Innovage Holding Corp (INNV) at Overweight - StreetInsider.com
streetinsider.com - March 29 at 3:11 PM
Barclays Initiates Coverage on InnovAge (OTCMKTS:INNV)Barclays Initiates Coverage on InnovAge (OTCMKTS:INNV)
americanbankingnews.com - March 29 at 11:12 AM
Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell Initiates Coverage on InnovAge (OTCMKTS:INNV)Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell Initiates Coverage on InnovAge (OTCMKTS:INNV)
americanbankingnews.com - March 29 at 8:58 AM
InnovAge (OTCMKTS:INNV) Coverage Initiated at William BlairInnovAge (OTCMKTS:INNV) Coverage Initiated at William Blair
americanbankingnews.com - March 29 at 8:58 AM
InnovAge (OTCMKTS:INNV) Receives New Coverage from Analysts at Piper SandlerInnovAge (OTCMKTS:INNV) Receives New Coverage from Analysts at Piper Sandler
americanbankingnews.com - March 29 at 8:58 AM
The Goldman Sachs Group Initiates Coverage on InnovAge (OTCMKTS:INNV)The Goldman Sachs Group Initiates Coverage on InnovAge (OTCMKTS:INNV)
americanbankingnews.com - March 29 at 8:58 AM
Otonomy (NASDAQ:OTIC) and InnovAge (OTCMKTS:INNV) Head-To-Head ContrastOtonomy (NASDAQ:OTIC) and InnovAge (OTCMKTS:INNV) Head-To-Head Contrast
americanbankingnews.com - March 27 at 6:32 PM
InnovAge (OTCMKTS:INNV) Sets New 1-Year High at $27.18InnovAge (OTCMKTS:INNV) Sets New 1-Year High at $27.18
americanbankingnews.com - March 22 at 6:22 PM
Innovus Pharmaceuticals Inc (INNV) CEO, President and Director Maureen Hewitt Bought $248,897 ...Innovus Pharmaceuticals Inc (INNV) CEO, President and Director Maureen Hewitt Bought $248,897 ...
finance.yahoo.com - March 12 at 11:54 PM
InnovAge Announces Exercise of Underwriters’ Option to Purchase Additional SharesInnovAge Announces Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - March 12 at 6:53 PM
InnovAge, an Elder-Care IPO, Gains on First DayInnovAge, an Elder-Care IPO, Gains on First Day
finance.yahoo.com - March 4 at 2:00 PM
InnovAge CEO on IPO debut: we’re excited about this transformational changeInnovAge CEO on IPO debut: we’re excited about this 'transformational change'
finance.yahoo.com - March 4 at 2:00 PM
Innovus Pharma Announces Receipt of Notification to Commercialize Zestra® in the European UnionInnovus Pharma Announces Receipt of Notification to Commercialize Zestra® in the European Union
www.bloomberg.com - May 23 at 10:28 PM
Innovus Pharma Signs Exclusive License and Distribution Agreement with Elis Pharmaceuticals for Zestra® in LebanonInnovus Pharma Signs Exclusive License and Distribution Agreement with Elis Pharmaceuticals for Zestra® in Lebanon
www.bloomberg.com - April 25 at 10:54 PM
Aytu BioScience and Innovus Pharmaceuticals Announce Effectiveness of Form S-4 Registration Statement Related to PropoAytu BioScience and Innovus Pharmaceuticals Announce Effectiveness of Form S-4 Registration Statement Related to Propo
www.bloomberg.com - March 28 at 10:17 PM
Aytu Bio +5% premarket on filing Form S-4Aytu Bio +5% premarket on filing Form S-4
seekingalpha.com - December 24 at 8:37 AM
INNV: Progress continues – raising target priceINNV: Progress continues – raising target price
finance.yahoo.com - August 15 at 5:04 PM
Innovus Pharmaceuticals (INNV) CEO Bassam Damaj on Q2 2019 Results - Earnings Call TranscriptInnovus Pharmaceuticals' (INNV) CEO Bassam Damaj on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - August 13 at 10:27 PM
Innovus Pharma Reports Quarterly Revenue for the Second Quarter 2019 of $6.8 million, a 27.7% Increase from Prior QuarterInnovus Pharma Reports Quarterly Revenue for the Second Quarter 2019 of $6.8 million, a 27.7% Increase from Prior Quarter
finance.yahoo.com - August 13 at 5:26 PM
Innovus Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 13, 2019Innovus Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 13, 2019
finance.yahoo.com - August 9 at 10:11 AM
Innovus Pharmaceuticals Announces that its Delta Prime Savings Club E-Commerce Marketplace is on Track for Annual Sales of Approximately $3 million in 2019Innovus Pharmaceuticals Announces that its Delta Prime Savings Club E-Commerce Marketplace is on Track for Annual Sales of Approximately $3 million in 2019
finance.yahoo.com - August 1 at 5:01 PM
Innovus Pharmaceuticals Announces Progress in Fulfilling the Regulatory and Manufacturing Steps to Receive Market Authorization for FlutiCare® in CanadaInnovus Pharmaceuticals Announces Progress in Fulfilling the Regulatory and Manufacturing Steps to Receive Market Authorization for FlutiCare® in Canada
finance.yahoo.com - June 19 at 10:27 AM
Cannabis and OTC Medications Gain Health Canada Approval with Rise of Cannabis/Wellness MarketCannabis and OTC Medications Gain Health Canada Approval with Rise of Cannabis/Wellness Market
finance.yahoo.com - June 19 at 10:27 AM
SmallCap Sentinel: As Fears Abate, an Array of Positive Factors Align for Drug MakersSmallCap Sentinel: As Fears Abate, an Array of Positive Factors Align for Drug Makers
www.marketwatch.com - June 11 at 5:00 PM
Muscle and Repair Treatments versus Surgery - Europe and Global Markets offer Big OpportunitiesMuscle and Repair Treatments versus Surgery - Europe and Global Markets offer Big Opportunities
finance.yahoo.com - June 11 at 11:07 AM
Innovus Pharma to market and sell CarvaNum in EuropeInnovus Pharma to market and sell CarvaNum in Europe
seekingalpha.com - June 6 at 10:48 AM
Innovus Pharma expands OTC drug pipelineInnovus Pharma expands OTC drug pipeline
seekingalpha.com - June 4 at 10:33 AM
The Pain Gain: More OTC Pain Alternatives see Continued GrowthThe Pain Gain: More OTC Pain Alternatives see Continued Growth
finance.yahoo.com - June 4 at 10:33 AM
Innovus Pharma Releases Results from Annual Shareholders MeetingInnovus Pharma Releases Results from Annual Shareholders Meeting
finance.yahoo.com - May 30 at 10:31 AM
Innovus Pharmaceuticals, Inc.: Innovus Pharma Management to Present at the 9th Annual LD Micro InvitationalInnovus Pharmaceuticals, Inc.: Innovus Pharma Management to Present at the 9th Annual LD Micro Invitational
www.finanznachrichten.de - May 29 at 10:19 AM
Innovus Pharma Management to Present at the 9th Annual LD Micro InvitationalInnovus Pharma Management to Present at the 9th Annual LD Micro Invitational
finance.yahoo.com - May 29 at 10:19 AM
Following Its Recent Approval from Health Canada for the Relief of Neuropathy Pain, Innovus Pharma Announces Receipt of Notification to Commercialize Diabasens® in the European UnionFollowing Its Recent Approval from Health Canada for the Relief of Neuropathy Pain, Innovus Pharma Announces Receipt of Notification to Commercialize Diabasens® in the European Union
finance.yahoo.com - May 28 at 10:20 AM
Innovus Pharmaceuticals, Inc. (INNV) CEO Bassam Damaj on Q1 2019 Results - Earnings Call TranscriptInnovus Pharmaceuticals, Inc. (INNV) CEO Bassam Damaj on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 16 at 7:17 AM
Innovus Pharma Reports Quarterly Revenue for the First Quarter 2019 of $5.4 Million, a 18.0% Increase from Comparable Quarter in the Prior YearInnovus Pharma Reports Quarterly Revenue for the First Quarter 2019 of $5.4 Million, a 18.0% Increase from Comparable Quarter in the Prior Year
finance.yahoo.com - May 15 at 5:24 PM
Innovus Pharma’s Partner Lavasta Receives Approval from Algeria to Market and Sell Zestra® and Zestra Glide® in that CountryInnovus Pharma’s Partner Lavasta Receives Approval from Algeria to Market and Sell Zestra® and Zestra Glide® in that Country
finance.yahoo.com - May 13 at 10:35 AM
Innovus to sell Taros minoxidil foamInnovus to sell Taro's minoxidil foam
seekingalpha.com - May 8 at 10:28 AM
Innovus Pharma Announces a Second Partnered United States OTC ANDA for Minoxidil 5% Foam for Men and WomenInnovus Pharma Announces a Second Partnered United States OTC ANDA for Minoxidil 5% Foam for Men and Women
finance.yahoo.com - May 8 at 10:28 AM
Innovus Pharma sees Q1 2019 revenue of ~$5.4MInnovus Pharma sees Q1 2019 revenue of ~$5.4M
seekingalpha.com - May 6 at 10:29 AM
Innovus Pharmaceuticals Reports Preliminary Q1 2019 Sales Revenue of Approximately $5.4 millionInnovus Pharmaceuticals Reports Preliminary Q1 2019 Sales Revenue of Approximately $5.4 million
finance.yahoo.com - May 6 at 10:29 AM
Innovus Pharma Announces FDA Approval of New ANDA for Supply of FlutiCare®Innovus Pharma Announces FDA Approval of New ANDA for Supply of FlutiCare®
finance.yahoo.com - April 18 at 5:29 PM
Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
finance.yahoo.com - April 18 at 5:29 PM
INNV: A subtle but important shift in prioritiesINNV: A subtle but important shift in priorities
finance.yahoo.com - April 8 at 5:38 PM
Innovus Pharma Reports Record Annual Revenue for Fiscal 2018 of $24.0 million in line with Previous Guidance and Product Gross Margins of 81%Innovus Pharma Reports Record Annual Revenue for Fiscal 2018 of $24.0 million in line with Previous Guidance and Product Gross Margins of 81%
finance.yahoo.com - April 1 at 5:01 PM
Innovus Pharmaceuticals IncInnovus Pharmaceuticals Inc
www.bloomberg.com - March 22 at 5:15 PM
Innovus Pharmaceuticals announces interim 2018 salesInnovus Pharmaceuticals announces interim 2018 sales
seekingalpha.com - March 21 at 5:20 PM
Innovus Pharmaceuticals Reports Preliminary Annual 2018 Net Revenue of $24 MillionInnovus Pharmaceuticals Reports Preliminary Annual 2018 Net Revenue of $24 Million
finance.yahoo.com - March 21 at 9:26 AM
Innovus Pharma Announces the Launch of its Diabasens® Product in CanadaInnovus Pharma Announces the Launch of its Diabasens® Product in Canada
finance.yahoo.com - March 6 at 10:44 AM
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.